A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer

[1]  D. Ettinger,et al.  A phase II study of bisantrene in advanced refractory breast cancer: An Eastern Cooperative Oncology Group pilot study , 1985, American Journal of Clinical Oncology.

[2]  G. Hortobagyi,et al.  Five‐day continuous‐infusion vinblastine in the treatment of breast cancer , 1985, Cancer.

[3]  F. Cavalli,et al.  Phase II evaluation of bisantrene in metastatic breast cancer. , 1985, Cancer treatment reports.

[4]  G. Hortobagyi,et al.  A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma , 1985, Cancer.

[5]  C. Coltman,et al.  Bisantrene, biological and clinical effects. , 1984, Cancer Treatment Reviews.

[6]  C. Osborne,et al.  Bisantrene, an active drug in patients with advanced breast cancer. , 1984, Cancer treatment reports.

[7]  J. Kuhn,et al.  Anaphylactoid reactions associated with bisantrene infusions , 1983, Investigational New Drugs.

[8]  G. Bodey,et al.  Bisantrene, an active new drug in the treatment of metastatic breast cancer. , 1983, Cancer research.

[9]  G. Bodey,et al.  Potential cardiotoxicity with mitoxantrone. , 1982, Cancer treatment reports.

[10]  G. Bodey,et al.  Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene). , 1982, Cancer treatment reports.

[11]  R. Benjamin,et al.  Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer , 1982, Cancer.

[12]  D. Alberts,et al.  Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay. , 1982, Cancer research.

[13]  R. Angier,et al.  Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. , 1982, Cancer research.

[14]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[15]  C. Coltman,et al.  Activity of 9–10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system , 1981, Cancer Chemotherapy and Pharmacology.

[16]  C. Coltman,et al.  Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942). , 1981, Cancer research.

[17]  G. Hortobagyi,et al.  Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. , 1980, Cancer treatment reports.

[18]  G. Hortobagyi,et al.  Adriamycin and mitomycin C: possible synergistic cardiotoxicity. , 1978, Cancer treatment reports.

[19]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[20]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.

[21]  J. Kovach,et al.  Regional targeting of Bisantrene by directed intravascular precipitation , 2004, Cancer Chemotherapy and Pharmacology.

[22]  W. Wood,et al.  Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[23]  D. D. Hoff,et al.  A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study) , 2004, Investigational New Drugs.

[24]  M. Staquet,et al.  New anticancer drugs : mitoxantrone and bisantrene , 1983 .

[25]  F. Muggia,et al.  Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule. , 1982, Cancer research.

[26]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[27]  Hypersensitivity reactions in cancer chemotherapy , 1981 .